title: Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
abstract: OBJECTIVE
  To study the association between cyclin D1 (CCND1) polymorphic variants and acute lymphoblastic leukemia (ALL) and breast cancer cases and the possibility of having different (CCND1) polymorphic variants in the development of ALL and breast cancer. In addition, to study the association between the different CCND1 polymorphic variants and the response to induction chemotherapy in ALL cases and clinicobiological parameters in breast cancer.
  
  
  METHODS
  We evaluated the association of CCND1 G870A polymorphism with ALL risk in 25 ALL patients and 15 healthy controls and with breast cancer risk in 30 newly diagnosed breast cancer female patients and in 25 healthy controls. Restriction Fragment Length Polymorphism (RFLP) polymerase chain reaction (PCR) was used for analysis of G870A polymorphism of CCND1 on anticoagulated whole blood of both the ALL and breast cancer cases and control groups.
  
  
  RESULTS
  The frequency of the AA genotype was significantly increased in the ALL cases while GG genotype was significantly increased in the control group. Furthermore, there was a highly statistically significant association between the A allele in the homozygous state AA and the ALL cases. Furthermore, there was a positive risk of developing ALL when having the AA genotype and the results were highly significant for AA genotype compared to GG genotype. For breast cancer, the results revealed that there was a positive risk association for those carrying the CCND1 A allele in the development of breast cancer.
  
  
  CONCLUSIONS
  Homozygosity for CCND1 A allele was associated with ALL patients and was a risk factor for ALL development, while the presence of the A allele, whether in homozygous or heterozygous state was associated with breast cancer cases and was a risk for breast cancer .Homozygosity for CCND1 G allele was associated with the control group.
authors.affiliation: Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt. dr_ahmed_bedewy@yahoo.com
authors.forename: A M L
authors.initials: AM
authors.lastname: Bedewy
authors.forename: M H
authors.initials: MH
authors.lastname: Mostafa
authors.forename: A A
authors.initials: AA
authors.lastname: Saad
authors.forename: S M
authors.initials: SM
authors.lastname: El-Maghraby
authors.forename: M M L
authors.initials: MM
authors.lastname: Bedewy
authors.forename: A M
authors.initials: AM
authors.lastname: Hilal
authors.forename: L S
authors.initials: LS
authors.lastname: Kandil
mesh_terms: D000328:Adult; D000368:Aged; D054458:Amplified Fragment Length Polymorphism Analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D019938:Cyclin D1 / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009010:Monte Carlo Method; D010641:Phenotype; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C530104:CCND1 protein, human; D019938:Cyclin D1